(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.


10


Reuters

Latest News

Ynet: Turkey reportedly extradited suspect of attempted assassination of Hamas official to Lebanon

Ynet: Pence: Timetable for unveiling US peace plan depends on Palestinians

FOX: The Latest: Official: Seek high ground amid tsunami warning

FOX: 7.9 earthquake hits near Kodiak, AK

CNN: Did Trump just start a trade war with China?

CNN: Opioid commission member: Our work is a 'sham'

CNN: This is your brain on music

Wall Street Journal: Tesla Gives Musk New Long-Term Pay Deal

Wall Street Journal: Manufacturers Fight Over New Tariffs' Effect on U.S. Jobs

Wall Street Journal: As U.S. Fires Trade Shot at China, Multinationals Caught in Crossfire

Wall Street Journal: Tesla Gives Musk New Long-Term Pay Deal

Daily Mail: Video: Take a look inside the sumptuous Viroth's Hotel in Cambodia

Daily Mail: Alexis Sanchez goes top of the Premier League wage table

Reuters: BRIEF-Unum To Acquire Poland-Based Pramerica ┼╗ycie

Reuters: MOVES-SSGA names Ludovic Djebali head of SPDR ETFs for France

Reuters: BRIEF-F.N.B. Corp Reports Q4 Earnings Per Share $0.07

Reuters: BRIEF-Bill Barrett Corp Sees Preliminary 2018 Drilling And Completion Capex Of $500 Mln-$600 Mln

Reuters: BRIEF-Leucrotta Announces Update On Operations And Financial Position

Reuters: BRIEF-Secoo Holding Announces Strategic Partnership With Parkson Retail Group

Reuters: BRIEF-Sol Gel Technologies Sees IPO Of 5 Mln Ordinary Shares

Reuters: UPDATE 2-Musk may get no salary unless Tesla hits milestones

NewYorkTimes: North Korea Signals It Might Hold Military Parade on Eve of Olympics

BBC: Kilmarnock goalkeeper Jamie MacDonald signs new deal